最新ニュース Bruker (NASDAQ:BRKR) 株価情報

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Bruker Corp

In the preceding three months, 5 analysts have released ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bruker, presenting an average target of $68.6, a high estimate of $80.00, and a low estimate of $60.00. Experiencing a 11.2% decline, the current average is now lower than the previous average price target of $77.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739221242_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bruker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Get to Know Bruker Better</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Financial Milestones: Bruker's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Bruker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.37% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bruker's net margin is impressive, surpassing industry averages. With a net margin of 4.73%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bruker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.27% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bruker's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.68%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.34, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BRKR

Bruker Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

WIIM

Bruker shares are trading lower after Barclays cut its price target on the stock from $69 to $65.

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $69 to $65.

News

Price Target

Barclays Maintains Overweight on Bruker, Lowers Price Target to $65

Guggenheim analyst Subbu Nambi reiterates Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Buy.

Reiteration

Guggenheim Reiterates Buy on Brukerto Buy

Guidance

Bruker Expects Q4 2024 Revenue Between $970M-$980M; Projects 2025 Constant Exchange Rate Revenue Growth In Upper Mid-Single Digits

"We respectfully disagree with the District Court's decision to grant an injunction with respect to sales of GeoMx products to new customers in the United States and we expect to promptly seek a stay of any injunction that is finally ordered," said Todd Garland, President of the Bruker Spatial Biology division. "We also look forward to the appeal of our case being heard by the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes. We remain steadfast in our view that the patents that were licensed by 10x and asserted against us are invalid and describe a fundamentally different method than what is used by the GeoMx system. We strongly believe that we should be vindicated on appeal. Bruker remains dedicated to ensuring that the scientific community has the freedom to select the best spatial biology platforms to advance their research."

Management

Bruker Comments On Delaware District Court's Post-Trial Ruling In Case Involving GeoMx Digital Spatial Profiler Products; Says  "We Look Forward To The Appeal Of Our Case Being Heard By The U.S. Court Of Appeals For The Federal Circuit... We Strongly Believe That We Should Be Vindicated On Appeal."

Legal

Reported Earlier, Delaware Jury Awards 10x Genomics $31.7M In Patent Case Against NanoString; Permanent Injunction On GeoMx Takes Effect January 10, 2025, With Royalties For Existing Installations; Additional Rulings On CosMx Expected Spring 2025

The instrument, located at the University of Zürich, is the second 1.2 GHz NMR in Switzerland, with the first at ETH used for developing solid-state NMR techniques, and studying materials and biological systems.

Bruker Reveals 1.2 GHz NMR Spectrometer At Swiss High-field NMR Facility

Guggenheim analyst Subbu Nambi initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy rating and announces Price Target of $72.

Initiation

Guggenheim Initiates Coverage On Bruker with Buy Rating, Announces Price Target of $72

B of A Securities analyst Derik De Bruin maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and raises the price target from $78 to $80.

B of A Securities Maintains Buy on Bruker, Raises Price Target to $80

Analysts' ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $70.0, a high estimate of $75.00, and a low estimate of $60.00. Highlighting a 10.06% decrease, the current average has fallen from the previous average price target of $77.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1733864514_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bruker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Terence Malone</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Terence Malone</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bruker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bruker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bruker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Unveiling the Story Behind Bruker</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>A Deep Dive into Bruker's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Bruker showcased positive performance, achieving a revenue growth rate of 16.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bruker's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bruker's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.68%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Bruker's debt-to-equity ratio surpasses industry norms, standing at 1.34. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bruker Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Arun Jayaram upgraded ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Neutral to Overweight and raised the price target from $120 to $123. ConocoPhillips shares closed at $103.51 on Wednesday. <a href="https://www.benzinga.com/quote/COP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Matthew Sykes upgraded the rating for Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Sell to Neutral and maintained the price target of $60. Bruker shares closed at $59.50 on Wednesday. <a href="https://www.benzinga.com/quote/BRKR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley analyst Meta Marshall upgraded Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from Equal-Weight to Overweight and raised the price target from $23 to $28. Hewlett Packard shares closed at $21.76 on Wednesday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Emmanuel Rosner upgraded the rating for Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Peer Perform to Outperform. Mobileye Global shares closed at $17.08 on Wednesday. <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Peter Weed upgraded Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Market Perform to Outperform and boosted the price target from $123 to $129. Okta shares closed at $86.11 on Wednesday. <a href="https://www.benzinga.com/quote/OKTA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying COP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-1024x563.png" alt="" class="wp-image-678536" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/05081347/image-49.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42332881/dow-settles-above-45000-for-first-time-investor-sentiment-improves-fear-greed-index-in-greed-zone">Dow Settles Above 45,000 For First Time As Salesforce, Marvell Surge: Investor Sentiment Improves, Fear Index In &#8216;Greed&#8217; Zone</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

MBLY

OKTA

This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Goldman Sachs analyst Matthew Sykes upgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Sell to Neutral and maintains the price target from $60 to $60.

Goldman Sachs Upgrades Bruker to Neutral, Maintains Price Target to $60

Bruker shares are trading higher after the company's President and CEO disclosed share purchases.

U.S. stocks were lower, with the Nasdaq Composite falling more than 200 points on Wednesday.
Shares of Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) rose sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/WSM/earnings">better-than-expected third-quarter financial results.</a>
The company reported third-quarter adjusted earnings per share of $1.96, beating the analyst consensus of $1.78. Quarterly sales declined by 2.9% year-over-year to $1.8 billion, beating the street view of $1.79 billion. Comparable brand revenue was down 2.9% year-over-year.
Also, the company approved a $1 billion stock repurchase authorization.
Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) shares gained 22.7% to $168.48 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares jumped 35.3% to $6.41. Palladyne AI and Red Cat expanded partnership for Teal Drones.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares surged 33.3% to $6.12. The company reported third-quarter earnings on Tuesday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) rose 18.3% to $7.39.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) gained 18.2% to $4.0701.</li>
<li>Wix.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) gained 14.5% to $210.79 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>ATRenew Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NASDAQ">RERE</a>) gained 13.8% to $2.8000 following third-quarter results.</li>
<li>Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares rose 10.5% to $47.24 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue outlook.</li>
<li>HUTCHMED (China) Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) gained 10.1% to $18.44. HUTCHMED announced the appointment of independent non-executive director and member of board committee.</li>
<li>Dolby Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) gained 9.9% to $77.96 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY25 EPS guidance above estimates.</li>
<li>Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) rose 9.2% to $52.69.</li>
<li>Azenta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) gained 9.2% to $44.68. Flex will replace Azenta in the S&amp;P MidCap 400, and Azenta will replace Envestnet in the S&amp;P SmallCap 600 effective prior to the opening of trading on Monday, Nov. 25.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) gained 6.6% to $11.82.</li>
<li>Flex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) gained 6.3% to $39.69.</li>
<li>Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose 5.2% to $160.02 after the company reported better-than-expected quarterly financial results. Also, multiple firms raised their respective price targets on the stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42086593/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Intraday Update

Movers

ALHC

AZTA

FLEX

GLBE

KEYS

NOVA

RCAT

RERE

TKNO

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday

DFLI

Dragonfly Energy Signs Memorandum Of Understanding With Bruker To Collaborate And Improve Current And Next-Generation Battery Technology And Battery Materials

Bruker Reveals EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform

Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) posted better-than-expected third-quarter results, but lowered <a href="https://www.benzinga.com/quote/BRKR/earnings">its FY24 guidance on Tuesday.</a>
Bruker posted adjusted earnings of 60 cents per share, beating market estimates of 59 cents per share. The company posted sales of $864.400 million versus expectations of $859.384 million.
Frank H. Laukien, Bruker&#8217;s President and CEO, commented, &#8220;Despite biopharma and China recovery delays, orders for our differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions are gradually improving, with upper mid-single digit BSI organic bookings growth in Q3 year-over-year. However, nascent biopharma and China recoveries will not benefit our fiscal year 2024 anymore, and accordingly we are lowering our FY2024 guidance. Integrating and improving our strategic acquisitions is making good progress and will further accelerate Bruker&#8217;s remarkable transformation. We are confident in our ability to drive above-market organic revenue growth with significant margin expansion in 2025.&#8221;
Bruker shares fell 1.9% to trade at $60.15 on Wednesday.
These analysts made changes to their price targets on Bruker following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6554fd65a571ee0001ec9bce/terence-malone">Barclays analyst Terence Malone</a> maintained Bruker with an Overweight and lowered the price target from $75 to $69.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Bruker with an Overweight and lowered the price target from $78 to $75.</li>
<li>TD Cowen analyst Dan Brennan maintained the stock with a Hold and lowered the price target from $72 to $70.</li>
<li>Citigroup analyst Patrick Donnelly maintained Bruker with a Buy and cut the price target from $80 to $75.</li>
</ul>
Considering buying BRKR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-1024x576.png" alt="" class="wp-image-633525" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06140559/image-60.png 1157w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41775237/amazon-disney-dupont-leidos-and-a-financial-stock-on-cnbcs-final-trades">Amazon, Disney, DuPont, Leidos And A Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>

Earnings

Bruker Analysts Cut Their Forecasts After Q3 Results

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $80 to $75.

Citigroup Maintains Buy on Bruker, Lowers Price Target to $75

TD Cowen analyst Dan Brennan maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $72 to $70.

TD Cowen Maintains Hold on Bruker, Lowers Price Target to $70

U.S. commerce dept. sets export controls on certain lab instruments

Tempering Positive Sentiment Of AI In Biotech

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), retaining the price target of $75.00. Brandon ...

Bruker's Strategic Immunity to Export Controls Justifies Buy Rating

Guggenheim analyst Subbu Nambi maintained a Buy rating on Bruker (BRKR – Research Report) yesterday and set a price target of $72.00. The company's...

Guggenheim Sticks to Their Buy Rating for Bruker (BRKR)

Bruker Corporation Pivots To Capitalize Its Growing TAM

Life sciences stocks fall on NIH funding concerns

BofA analyst Michael Ryskin lowered the firm's price target on Bruker (BRKR) to $76 from $80 and keeps a Buy rating on the shares. The firm raised ...

Bruker price target lowered to $76 from $80 at BofA

In a report released today, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target of $...

Wells Fargo Sticks to Their Buy Rating for Bruker (BRKR)

Barclays analyst Luke Sergott lowered the firm's price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm expe...

Bruker price target lowered to $65 from $69 at Barclays

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President ...

Trump Trade: President to impose 25% tariffs on steel, aluminum imports

AMGN

AMZN

AVTR

CENX

GILD

GOOG

GOOGL

ILMN

MRKR

MSFT

NVDA

NVSEF

ORCL

PACB

PINS

PPTDF

QGEN

RDDT

RVTY

RXRX

SNAP

STLD

TCGGY

TCHBF

TECH

TSLA

Press Releases

General

Dragonfly Energy and Bruker Partner to Accelerate Battery Technology Development

Bruker Corporation to Present at Upcoming Investor Conferences

Bruker Announces Quarterly Dividend

Bruker Introduces Dimension Nexus™ Atomic Force Microscope

Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

Bruker Comments on Delaware District Court's Post-Trial Ruling in Case Involving GeoMx Digital Spatial Profiler Products

Bruker Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research

Bruker Announces Date and Time of Fourth Quarter 2024 Earnings Release and Webcast

DFLIW

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bruker

ニュース

最新ニュース Bruker (NASDAQ:BRKR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル